The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504.
 
Marc Saul Schwartz
No Relationships to Disclose
 
Deepa Jeyakumar
No Relationships to Disclose
 
Lloyd Earl Damon
Honoraria - Actelion (I); Boston Scientific (I); Gilead Sciences (I)
Consulting or Advisory Role - Actelion (I); Atara Biotherapeutics; Boston Scientific (I); Gilead Sciences (I); Jazz Pharmaceuticals; Respira Therapeutics (I)
Speakers' Bureau - Novartis (I)
Research Funding - Astellas Pharma; Novartis; Sigma-Tau
 
Gary J. Schiller
Consulting or Advisory Role - University of California
Research Funding - University of California
 
Matthew Joseph Wieduwilt
Stock and Other Ownership Interests - Reata Pharmaceuticals
Research Funding - ADC Therapeutics (Inst); Amgen (Inst); Cantex (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Shire (Inst); Sigma-Tau (Inst)